# US 2023/0067928 A1 · Methods for prognosing and preventing metastatic liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067928 A1
- Document ID: US20230067928A1
- Status: Published application
- Kind: A1
- Application number: 17/869,948
- Filed: 2022-07-21
- Published: 2023-03-02
- Earliest claimed: 2014-10-07
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: David C. LYDEN; Bruno COSTA DA SILVA
- Web page: https://patentgrep.com/patent/US20230067928A1

## CPC

- G01N 33/57525: of the liver or pancreas
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N 2333/46: from vertebrates
- G01N 2333/70557: Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
- G01N 2333/70585: CD44
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/715: for cytokines; for lymphokines; for interferons
- G01N 2333/90245: acting on paired donors with incorporation of molecular oxygen (1.14)
- G01N 2333/96494: Matrix metalloproteases, e. g. 3.4.24.7
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention is directed to a method for identifying an individual who is at risk for developing metastatic liver disease that involves measuring, in a sample isolated from the individual, exosomal levels of one or more markers of metastatic liver disease. Kits for carrying out this method are also disclosed. The present invention also relates to a method of preventing metastatic liver disease in an individual who are at risk for developing the disease that involves administering one or more inhibitors of liver premetastatic niche formation.

## Claims

### Claim at position 1

-35. (canceled)

### Claim 36

A method of identifying a subject having or at risk of developing metastatic liver disease, said method comprising:
measuring, in a liver cell sample isolated from the subject, expression levels of one or more markers of liver pre-metastatic niche formation selected from the group consisting of matrix metallopeptidase 9 (MMP9), S100 protein B (S100B), S100 protein A8 (S100A8), connective tissue growth factor (CTGF), endothelin (EDN), platelet-derived growth factor (PDGF), C-C motif chemokine 2 (CCL2), fibroblast growth factor-2 (FGF2), hepatocyte growth factor (HGF), interleukin-1 (IL-1), interleukin-6 (IL-6), insulin-like growth factor (IGF), transforming growth factor-beta (TGFβ) and vascular endothelial growth factor (VEGF);
comparing the measured expression levels of the one or more markers of liver pre-metastatic niche formation to expression levels of the one or more markers of liver pre-metastatic niche formation in a control sample; and
identifying the subject as having or at risk of developing liver metastases when said subject has increased expression levels of the one or more markers of liver pre-metastatic niche formation relative to control expression levels of the one or more markers of liver pre-metastatic niche formation.

### Claim 37 (depends on 36)

The method of claim 36 further comprising:
measuring, in a sample isolated from the subject, exosomal levels of one or more markers of metastatic liver disease selected from the group consisting of Annexin Al (ANXA1), CD44, CD47, cadherin 1 (CDH1), filamin A (FLNA), high mobility group box 1 (HMGB1), integrin β3 (ITGB3), lectin galactoside-binding soluble 1 (LGALS1), lectin galactoside-binding soluble 3 (LGALS3), macrophage migration inhibitory factor (MIF), matrix metalloproteinase 14 (MMP14), plasminogen activator urokinase receptor (PLAUR), prostaglandin-endoperoxide synthase 2 (PTGS2), and ras-related C3 botulinum toxin substrate 1 (RAC1);
comparing the measured exosomal levels of the one or more markers of metastatic liver disease to exosomal levels of the one or more markers of metastatic liver disease in a control sample to identify increased exosomal levels of the one or more markers of metastatic liver disease in the sample, wherein said subject is identified as having or at risk of developing liver metastases when said subject has increased expression levels of the one or more markers of liver pre-metastatic niche formation relative to control expression levels and increased exosomal levels of the one or more markers of metastatic liver disease relative to control exosomal levels.

### Claim at position 4

-50. (canceled)

### Claim 51 (depends on 36)

The method of claim 36, wherein the subject has a gastrointestinal tract cancer.

### Claim 52 (depends on 51)

The method of claim 51, wherein the gastrointestinal tract cancer is in complete or partial remission.

### Claim 53 (depends on 51)

The method of claim 51, wherein the gastrointestinal tract cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, stomach cancer, anal cancer, esophageal cancer, gallbladder cancer, and rectal cancer.

### Claim 54 (depends on 36)

The method of claim 36, wherein the subject has a pre-tumoral gastrointestinal lesion.

### Claim 55 (depends on 54)

The method of claim 54, wherein the pre-tumoral gastrointestinal lesion is selected from the group consisting of pancreatitis, intraductual papillary mucinous neoplasia, pancreatic intraepithelial neoplasia, ulcerative colitis, Chron's disease, inflammatory bowel disease, colon polyps, rectal polyps, helicobacter pylori-associated gastritis, Barrett's esophagus, gallstones, porcelain gallbladder, choledochal cysts, gallbladder polyps, and primary sclerosing cholangitis.

### Claim 56 (depends on 36)

The method of claim 36, wherein said measuring comprises:
measuring expression levels of the one or more markers of liver pre-metastatic niche formation in the sample using an immunoassay.

### Claim 57 (depends on 56)

The method of claim 56, wherein the immunoassay is selected from the group consisting of immunohistochemical assay, radioimmunoassay, enzyme-linked immunosorbent assay (ELISA), immunoradiometric assay, gel diffusion precipitation reaction, immunodiffusion assay, in situ immunoassay, Western blot, precipitation reaction, complement fixation assay, immunofluorescence assay, and immunoelectrophoresis assay.

### Claim 58 (depends on 56)

The method of claim 56, wherein said measuring comprises:
contacting the sample with one or more labeled binding reagents, wherein each labeled binding reagent is capable of binding to one of the one or more markers of liver pre-metastatic niche formation;
detecting the one or more labeled binding reagents bound to their respective marker of metastatic liver disease in the sample; and
measuring expression levels of one or more markers of liver pre-metastatic niche formation based on said detecting.

### Claim 59 (depends on 36)

The method of claim 36, wherein said measuring comprises:
measuring expression levels of the one or more markers of liver pre-metastatic niche formation in the sample using a nucleic acid detection assay.

### Claim 60 (depends on 59)

The method of claim 59, wherein the nucleic acid detection assay is selected from the group consisting of a quantitative polymerase chain reaction (qPCR) assay, a quantitative reverse-transcription PCR assay, a solid-phase nucleic acid detection assay, and a next-generation sequencing assay.

### Claim 61 (depends on 59)

The method of claim 59, wherein mRNA levels are measured.

### Claim 62 (depends on 61)

The method of claim 61, wherein said nucleic acid detection assay comprises:
synthesizing cDNA of the one or more markers of liver pre-metastatic niche formation mRNA of the one or more markers of liver pre-metastatic niche formation present in the sample;
contacting the sample with reagents suitable to detect the synthesized cDNA in the sample;
detecting the synthesized cDNA; and
measuring levels of the synthesized cDNA of the one or more markers of liver pre-metastatic niche formation in the sample based on said detecting.

### Claim 63 (depends on 36)

The method of claim 36, wherein the control sample is a sample derived from non-cancerous cells or tissue.

### Claim 64 (depends on 36)

The method of claim 36, wherein the control sample is a sample obtained from the subject at an earlier time point.
